The U.S. Department of Defense (DOD) is expanding the list of drugs that military service members will be tested for to include the psychedelic compound psilocin, one of the two main components of psilocybin mushrooms.
In a memo obtained by Marijuana Moment, a DOD employee performing the duties of the deputy under secretary of defense for personnel and readiness advised military leadership that psilocin will be added to the department’s Drug Demand Reduction Program drug testing panel effective October 1.
The memo, dated August 18, states that the policy change being made due to “the risk of impairment and subsequent deterioration of security, military fitness, readiness, good order and discipline.”
“Drug abuse by Service members is a safety and readiness issue, and the Department must adapt our detection and deterrence program to address new and emerging drug threats,” Dr. Merlynn Carson wrote.
The DOD official said that attachments to the memo lay out “cutoff concentrations” for a positive psilocin test and other drugs in the testing panel.
Marijuana Moment reached out to DOD for copies of those attachments, but representatives were not able to immediately provide the documents.
“The Department of Defense maintains a zero-tolerance policy prohibiting drug use, and we remain committed to continually expanding drug testing capabilities and enhancing our education and prevention efforts by providing effective information on drug misuse, including the use of Psilocin,” an official told Marijuana Moment in an email.
The memo says that the “first priority” for psilocin testing under the revised drug panel “will be given to specimens collected under the auspices of probable cause, consent, or command.”
“In proportion to laboratory capabilities and capacity, second priority will be given to special testing requests for other collection modes, such as routine inspection-based collections, and specimens may also be randomly tested for psilocin,” it says.
At the same time that DOD has moved to test for psilocin, it’s also carrying out a congressional mandated psychedelic therapy pilot program for active duty service members and veterans. A more recent spending bill covering DOD would require a “progress report” on that initiative.
This latest memo also comes about two months after a DOD contractor sued the federal government, alleging that questions about his past marijuana use during a security clearance process violated his Fifth Amendment right against self-incrimination.
While the latest DOD policy update concerned a psychedelic compound, questions about federal workers testing positive for marijuana have also ballooned in recent years, as more individual states have legalized the drug.
Keep reading
You must be logged in to post a comment.